Equities research analysts forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will report $5.74 billion in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for Gilead Sciences’ earnings, with the highest sales estimate coming in at $6.05 billion and the lowest estimate coming in at $5.27 billion. Gilead Sciences reported sales of $7.32 billion during the same quarter last year, which would suggest a negative year over year growth rate of 21.6%. The firm is scheduled to announce its next earnings report after the market closes on Tuesday, February 6th.

According to Zacks, analysts expect that Gilead Sciences will report full year sales of $5.74 billion for the current fiscal year, with estimates ranging from $25.42 billion to $26.21 billion. For the next financial year, analysts expect that the business will post sales of $21.76 billion per share, with estimates ranging from $19.77 billion to $23.34 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 EPS.

GILD has been the subject of a number of analyst reports. Mizuho restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Jefferies Group restated a “hold” rating and set a $93.00 price objective on shares of Gilead Sciences in a research note on Wednesday, October 4th. Bank of America decreased their price objective on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, October 4th. Oppenheimer initiated coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. Finally, CIBC initiated coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $85.53.

In related news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $79.00, for a total value of $2,370,000.00. Following the sale, the executive vice president now directly owns 57,114 shares in the company, valued at $4,512,006. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 591,666 shares of company stock valued at $44,466,567. Company insiders own 1.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Welch Investments LLC acquired a new stake in Gilead Sciences during the third quarter worth about $108,000. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences in the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences in the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences in the second quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management grew its holdings in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the period. 75.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences (NASDAQ GILD) traded down $0.19 during midday trading on Thursday, hitting $80.98. The company had a trading volume of 6,794,345 shares, compared to its average volume of 8,110,000. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market cap of $105,750.00, a PE ratio of 9.21, a P/E/G ratio of -1.76 and a beta of 1.13. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $86.27.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.

ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/01/21/analysts-anticipate-gilead-sciences-inc-gild-will-post-quarterly-sales-of-5-74-billion.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.